Enzon to Present at Banc of America Securities Specialty Pharmaceuticals Conference.

BRIDGEWATER, NJ -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that the company will participate in the Banc of America Securities Specialty Pharmaceuticals Conference which is being held July 28-30 in Southampton, New York. Ken Zuerblis, Enzon's chief financial officer, will give a 30-minute presentation that will consist primarily of Q&A on Thursday, July 29, 2004 at 9:45 a.m. EDT.

The presentation will be webcast live and may be accessed by visiting Enzon's website at www.enzon.com. A replay of the webcast will also be available on the Company's website.

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat life-threatening diseases. The Company has developed or acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed in North America by Enzon's specialized sales force. Enzon's science-focused strategy includes an extensive drug development program that leverages the Company's macromolecular engineering technology platforms, including PEG modification and single-chain antibody (SCA(R)) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional products and technologies. Enzon has several drug candidates in various stages of development, independently and with partners, including Onco TCS (vincristine sulfate liposomes injection), for which a U.S. marketing application has been submitted for the treatment of relapsed, aggressive non-Hodgkin's lymphoma. Further information about Enzon, this press release, and the conference call can be found on the Company's web site at www.enzon.com.